Moksotens tab. of p/o of 0.2 mg No. 20

Moksotens – antihypertensive medicine. Agonists of imidazolinovy receptors for treatment of arterial hypertension.

Structure

• active ingredient: moksonidin;
• 1 tablet supports a moksonidin, in terms of 100% substance of 0.2 mg;
• other components: lactose, monohydrate; povidone; krospovidon; magnesium stearate;
• mix for a film covering: gipromeloza; lactose, monohydrate; macrogoal; ferrous oxide yellow (E 172); ferrous oxide red (E 172); titan dioxide (E 171).

Moksonidin is contraindicated to

Contraindication

• hypersensitivity to active ingredient or to any component of drug;
• sick sinus syndrome;
• bradycardia (ChSS at rest lower than 50 ud. / mines);
• AV-blockade ІІ and ІІІ degrees;
• heart failure.

Side reactions

Frequent side reactions at reception of a moksonidin include dryness in a mouth, dizziness, an asthenia and drowsiness. These symptoms often decrease after the first several weeks of treatment.

from mentality: often – insomnia; infrequently – nervousness.

from nervous system: often – a headache *, dizziness, vertigo, drowsiness; infrequently – obmorok*.

from organs of hearing and a labyrinth: seldom – a ring in ears.

from a cardiovascular system: infrequently – bradycardia, hypotension * (including orthostatic hypotension).

from digestive tract: very often – dryness in a mouth; often – diarrhea, nausea, vomiting, dyspepsia.

from skin and hypodermic fabric: often – rash, an itching; infrequently – a Quincke's disease.

from a skeletal and muscular system and connective tissue: often dorsodynias; infrequently – neck pain.

Route of administration

Standard initial dose of a moksonidin makes 0.2 mg/days. The maximum single dose – 0.4 mg. The maximum daily dose – 0.6 mg – is applied in 2 receptions. The dose should be selected individually depending on reaction of the patient.

Moksonidin can be accepted irrespective of food, washing down with a small amount of liquid.

Feature of use

Use during pregnancy or feeding by a breast

Relevant data on use of a moksonidin. Researches on animals showed embriotoksichesky effect (see the section "Pharmacological Properties — Preclinical Data on Safety"). The potential risk for the person is unknown. Moksonidin it is not necessary to apply during pregnancy if there is no need.

Moksonidin gets into breast milk therefore it should not be applied during feeding by a breast. If therapy moksonidiny is considered necessary absolutely, feeding by a breast should be stopped.

Moksonidin is not recommended by

for use to children and teenagers (up to 18 years) because of insufficiency of data on safety and efficiency of medicament for this group of patients.

Ability to influence speed of response at control of motor transport or other mechanisms

Research of influence of medicament on ability to run motor transport or to work with other mechanisms were not carried out by

.

Treatment of arterial hypertension this medicine demands regular medical observation. Various reactions about which it was reported in some cases (for example, dizziness, drowsiness) can change reaction to such an extent that the ability to run motor transport, to work with other mechanisms or to work without means of safety worsens. It more belongs to the periods of an initiation of treatment, increase in a dose, change of medicament and interaction with alcohol.

Overdose

overdose Symptoms

In some cases the overdose of a moksonidin, even in the dose of 19.6 mg taken for 1 time did not lead to a lethal outcome. Signs and symptoms of overdose include a headache, sedation, drowsiness, arterial hypotension, dizziness, an asthenia, bradycardia, dryness in a mouth, vomiting, fatigue, pain in the upper site of a stomach. At heavy overdose the careful monitoring of emergence of disturbances of consciousness and respiratory depression is recommended.

Simultaneous use of medicament with other antihypertensive medicaments results

in additive effect.

As tricyclic antidepressants can reduce efficiency of antihypertensive medicaments of the central action, co-administration of these medicaments with moksonidiny is not recommended.

Moksonidin can enhance sedation of tricyclic antidepressants (co-administration should be avoided), tranquilizers, alcohol, sedative and sleeping medicines.

Storage conditions

In original packing at a temperature not above 25 °C. To store out of children's reach.